Exelixis Announces 3-Month FDA PDUFA Extension for Zanzalintinib NDA
EXELIXIS, INC.
Subscribe to track EXEL
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š¢ Exelixis ($EXEL) Form 8-K Regulatory Update
ā¢ Event: FDA extends NDA review period for zanzalintinib by 3 months ā¢ Indication: In combination with atezolizumab for metastatic colorectal cancer ā¢ Reason: Updated safety and efficacy data submission classified as a major amendment ā¢ New PDUFA Date: March 3, 2027
Comprehensive Analysis
Executive Summary
On September 11, 2026, Exelixis, Inc. ($EXEL) filed a Form 8-K reporting an update regarding the regulatory review timeline for its New Drug Application (NDA) for zanzalintinib.
Key Event Details
- Regulatory Action: The U.S. Food and Drug Administration (FDA) notified Exelixis on September 10, 2026, that it has extended the review period for the zanzalintinib NDA by three months.
- Indication & Combination: Zanzalintinib in combination with atezolizumab for the treatment of patients with metastatic colorectal cancer.
- Cause for Extension: In response to an FDA information request, Exelixis submitted updated safety and efficacy data. The agency determined this submission constitutes a major amendment to the application.
- Updated PDUFA Action Date: March 3, 2027.
Market & Trading Impact
- Significance: Medium. A three-month PDUFA extension due to a major amendment is standard regulatory procedure when significant additional data is provided during review; however, it postpones potential commercialization and cash flow generation by one quarter.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.